Lower-Risk MDS: Current and Future Treatment Strategies - Episode 4

MEDALIST Trial: Luspatercept in Patients with Lower-Risk MDS

, ,

Uwe Platzbecker, MD, reviews data updates from the MEDALIST trial investigating luspatercept in patients with lower-risk myelodysplastic syndrome.

EP. 1: Myelodysplastic Syndrome: Overview of Diagnosis, Classification, and Treatment
EP. 2: Clinical Insights into the COMMANDS Trial
EP. 3: Lower-Risk MDS: How Do Practice Patterns Compare Worldwide?
Now Viewing
EP. 4: MEDALIST Trial: Luspatercept in Patients with Lower-Risk MDS
EP. 5: Recent Updates for Second-Line Treatment Options in Lower-Risk MDS
EP. 6: Clinical Implications of Recent Data on New Agents in Lower-Risk MDS
EP. 7: Real-World Data for Luspatercept in Lower-Risk MDS
EP. 8: Treatment Strategies and Sequencing in MDS
EP. 9: Unmet Needs and Future of Lower-Risk MDS

Related Content:

Lower-Risk MDS: Current and Future Treatment StrategiesMoffitt Cancer CenterHematologic OncologyInsights
Asciminib and Ponatinib Sit at the Forefront of Advances in CML Management: Insights From Onyee Chan, MD; and Bradley D. Hunter, MD
Clinical Scenario 1: A HER2+ mBC Patient With Trastuzumab Deruxtecan With Brain Mets
Brief Overview of Synovial Sarcoma: What It Is, Clinical Presentation and Diagnosis